Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Paragon Genomics NGS Panel Captures New SARS-CoV-2 Mutations
  • USA - English

Several reports of the new SARS-CoV-2 mutations on the spike protein have been detected around the world, including the United Kingdom, South Africa, and the United States. Officials in both the United Kingdom and South Africa have said that the mutations were driving the countries' resurgence of the disease, with higher numbers of confirmed cases, hospitalizations, and deaths. To date, the FDA has identified three molecular assays whose performance could be impacted by SARS-CoV-2 genetic variants, and is suggesting that laboratories with access to quick-turnaround whole-genome sequencing services should consider further characterizing the specimen with genetic sequencing. The SARS-CoV-2 FLEX Panel by Paragon Genomics, Inc., is a full genome sequencing-based Coronavirus assay for detection, research and surveillance, with unique design elements that allow for more robust and confident variant calling, even when the virus mutates over time.


News provided by

Paragon Genomics

Jan 15, 2021, 12:00 ET

Share this article

Share toX

Share this article

Share toX

HAYWARD, Calif., Jan. 15, 2021 /PRNewswire-PRWeb/ -- Paragon Genomics, Inc., a leader in amplicon-based target enrichment solutions for next-generation sequencing (NGS) and precision medicine, today announced a solution for capturing the new mutations of the SARS-CoV-2 variants that have been sweeping across the United Kingdom and South Africa, and already finding its way in various countries worldwide.

The new UK (20B/501Y.V1, VOC 202012/01, or B.1.1.7 lineage) and South African (20C/501Y.V2, or B.1.351 lineage) SARS-CoV-2 variants contain mutations in the receptor binding domain (RBD) of the spike protein, leading to concern and alarm worldwide. Several EU countries have issued travel bans within the UK in an effort to stop the new variant from spreading further. Officials in both the UK and South Africa have said that these mutations are driving the countries' resurgence of the disease, with higher numbers of confirmed cases, hospitalizations and deaths.

These mutations in the spike protein have been shown to significantly increase infection rates, and may have further implications for the efficiency of the new vaccines and current test methods, confirming that a robust detection method and continued screening and surveillance are more critical than ever in our continued global efforts to control this pandemic.

The CleanPlex® SARS-CoV-2 FLEX Panel for full viral genome sequencing has been updated to specifically and confidently capture these new emerging mutations of this ever-evolving virus. The FLEX panel assay design covers the critical N501Y mutation and 69/70 deletion along with other mutations specific to these new variants. The FLEX panel is designed with the intention of evolving alongside the virus to support the front-end researchers and scientists in surveillance and monitoring efforts.

These new SARS-CoV-2 variants contain multiple spike protein mutations, including the N501Y mutation, one of six key contact residues within the Receptor-Binding Domain (RBD). This mutation has been shown to increase binding affinity of the virus to ACE2, the entry receptor for SARS-CoV-2 into human cells. Other mutations (especially the HV 69-70 deletion) have been shown to impact the efficacy of qPCR-based assays that specifically target the S protein. This inability to positively detect the virus leads to what is known as S-gene target failure (SGTF). This further confirms that qPCR-based assays, usually based on very few specific targets, can lead to false negative calls with the accumulation of SARS-CoV-2 mutations.

The FDA has identified the Mesa Biotech Accula SARS-CoV-2 Test, the Thermo Fisher Scientific TaqPath COVID-19 Combo Kit, and the Applied DNA Sciences Linea COVID-19 Assay Kit whose performance could be negatively affected by SARS-CoV-2 genetic variants. The agency put out a statement saying that local or state clinical laboratories with access to quick-turnaround whole-genome sequencing services should consider further characterizing the specimen with genetic sequencing when S gene dropout patterns appear.

A multi-target approach (such as Paragon's CleanPlex multiplex PCR-based targeted amplification approach) ensures much more confident detection of viral infection.

"Sequencing and monitoring of new mutations are critical, as there could be important implications on not only detection accuracy, but also on vaccine efficacy," said Paragon Genomics CEO, Tao Chen.

"The SARS-CoV-2 FLEX panel is built upon the original SARS-CoV-2 panel and contains additional critical design elements for detecting new mutations and variants over time. Specifically, this new panel contains degenerate primer designs of polymorphic regions of the SARS-CoV-2 genome to allow for more robust amplification of variable regions , thus improving coverage robustness for emerging variants."

Paragon's CleanPlex technology offers a variety of products for additional COVID-19 research such as in COVID-19 susceptibility through human ACE2 and TMPRSS2 complete sequencing, and common respiratory virus sequencing with the Respiratory Virus Research Panel that concurrently targets SARS-CoV-2, influenza A/B, and respiratory syncytial virus (RSV). The portfolio offers comprehensive solutions for confident SARS-CoV-2 detection, surveillance, and related research.

The team at Paragon Genomics has been vigilantly monitoring SARS-CoV-2 mutations since the initial emergence of this virus in late 2019 and will continue to stay on top of SARS-CoV-2 research progress to ensure that the best detection and surveillance solutions with robust coverage are provided to the scientific community worldwide.

For more information on Paragon Genomics' CleanPlex SARS-CoV-2 Flex panel and other COVID-19 related products, check out https://www.paragongenomics.com/.

CleanPlex NGS panels are for Research Use Only. They are not intended for disease diagnosis.

About Paragon Genomics

Paragon Genomics (https://www.paragongenomics.com) is a leader in amplicon-based target enrichment and library preparation solutions to accelerate the development of next-generation sequencing (NGS)-based assays for research and clinical testing. The company designs and manufactures high performance and ultra-multiplexed amplicon NGS library preparation products for analyzing difficult, clinically relevant samples. It strives to be the NGS assay partner of choice for research and clinical NGS labs and to make custom NGS assays easily available to a broad range of users. Privately held Paragon Genomics is located in Hayward, California.

Media Contact

Tao Chen, Paragon Genomics, +1 510-363-9918, [email protected]

SOURCE Paragon Genomics

Related Links

http://www.paragongenomics.com

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.